90 Y)-based radioembolization has been employed to treat hepatocellular carcinoma (HCC) as commercial radioactive glass and polymeric resin microspheres. However, in India and other Asian countries, these preparations must be imported and are expensive, validating the need for development of indigenous alternatives. This work was aimed to develop an economically and logistically favourable indigenous alternative to imported radioembolizing agents for HCC therapy.
In several Asian and African countries hepatocellular carcinoma (HCC) is the major cause of death from cancer 1, 2 . More than 80 per cent of HCC patients have inoperable disease with poor prognosis 3 : Two-thirds of patients survive less than two years, with less than five per cent achieving a five year survival rate [3] [4] [5] [6] .
The need for strict selection criteria to avoid postoperative liver failure (in case of concomitant liver cirrhosis) restricts the possibility of resective surgery to only 10-37 per cent of HCC cases [7] [8] [9] . The established anti-cancer drugs including sorafenib, tamoxifen and octreotide have proved ineffective in systemic HCC chemotherapy, with less than 20 per cent response rate and no significant survival benefit 7, 10, 11 . External beam radiotherapy has limited applicability for HCC, primarily due to the possibility of radiation induced liver disease (RILD) 12 . While percutaneous intervention (PI) with ethanol can achieve 90-100 per cent response rates in tumours <2 cm diameter, this drops to 50 per cent for tumours with ≥5 cm diameter 7, 13 .
Trans-arterial chemoembolization (TACE) has been practised for more than three decades 14, 15 , employing drugs like cisplatin, doxorubicin, methotrexate, paclitaxel, etc. in conjunction with lipiodol or other embolizing agents for regional therapy 16, 17 . Embolization in conjunction with a therapeutic radiopharmaceutical, viz. radioembolization, is more tumour specific vis-à-vis systemic radiotherapy, restricting damage to normal liver and diminishing RILD complications 18 .
The two principal approaches to radioembolization for HCC are: (i) Using lipiodol as a carrier of radioactivity. Iodine-131 ( 131 I) labelled lipiodol has been tested in clinical trials as a therapeutic radiopharmaceutical for HCC 19 , but the preparation is cumbersome, the 8.04 day half-life and 364keV gamma emissions may cause unnecessary nonspecific dose absorption, and stability of the exchange label may be an issue for extended in vivo use. 22 . In the Indian context, these preparations must be imported, and are in consequence beyond the economic reach of majority of the patients requiring treatment for HCC. 25, 26 , no literature pertaining to detailed biological studies performed with such microspheres has been encountered.
The work reported here focuses on the development and biological evaluation in animal model of a 90 Y-labelled Biorex 70 microsphere based embolization complex that may serve as a therapeutic vehicle for hepatocellular carcinoma.
Material & Methods
Biorex70 micro particulate cation exchange resin (200-400 dry mesh size, 45-75 μm wet bead size) was procured from Bio-rad, USA. Oxine (8-hydroxyquinoline), ammonium acetate, sodium chloride and sodium bicarbonate were obtained from Sigma, USA. Lipiodol was obtained from Guerbet, France. Ethanol and chloroform were procured from Merck, India. Double distilled water was used to prepare all solutions.
Male Sprague-Dawley rats employed in the animal studies were procured from the Animal House of the Advanced Centre for Treatment, Research and Education in Cancer -Tata Memorial Centre (ACTREC-TMC), Navi Mumbai, India. Animal studies were performed after due approval from the institutional animal ethics committee. N1S1 rat liver carcinoma cell line of Sprague-Dawley origin (ATCC CRL-1604) was procured by and cultured at ACTREC towards use in development of orthotopic animal tumour model for this study. Ethicon surgical sutures (Johnson & Johnson, India) were used during surgical procedures. BD Vacutainer® tubes (BecktonDickinson, India) suitable for whole blood and serum were used to collect blood for various investigations. For haemoglobin estimation, Drabkin's reagent was obtained from Sigma, USA. Kits for estimating serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were obtained from Bioquant, USA. Serum bilirubin was estimated using kit obtained from Bioscientific Corporation, USA. Serum alphafoetoprotein levels were estimated using ELISA kit from MP Biomedicals, USA.
Orbital shaker-incubator from Biosystem Scientific, India, was used for radiolabelling reactions. Radioactivity measurements for 90 Y-labelling studies were carried out using a well type NaI (Tl) scintillation detector (ECIL, India). Radioactivity measurements for in vivo distribution studies were performed on an integral line flat-bed NaI (Tl) scintillation detector (Harshaw, USA). In both cases, Bremsstrahlung radiation resulting from the β-emissions of 90 23 .
In the first step, electrolysis was performed for 90 min in 90 Sr(NO 3 ) 2 feed solution at pH 2-3 at a potential of -2.5V with 100-200 mA current using platinum electrodes. In the second electrolysis step, the platinum cathode on which 90 Y was deposited during the first cycle of electrolysis was used as anode and a fresh circular platinum electrode was used as cathode. The second electrolysis step was performed for 45 min in 3 mM HNO 3 at a potential of -2.5V with 100 mA current. 90 Y deposited on the cathode after the second electrolysis was dissolved in 0.1N HCl to obtain 90 YCl 3 .
Preparation of 90 Y -labelled Biorex 70 microspheres: Biorex 70 microspheres (5 mg) were suspended in one ml of freshly prepared 0.1 M ammonium acetate solution (pH 5.5-6.0). To this, up to 185 MBq of 90 YCl 3 was added. The pH was adjusted if necessary to ~5.0 using 0.1 N HCl. The above reaction mixture was kept on an orbital shaker incubator for different time periods at room temperature. At the end of the labelling reaction, the microspheres were separated by centrifugation at 1200×g for 10 min and washed twice with phosphate buffered saline (PBS). The percentage of 90 Y-activity associated with the microspheres in comparison to 90 Y-radioactivity in the reaction mixture was taken as the radiolabelling yield. Stability of the labelled product was tested by suspending it in PBS at 37°C, and measuring the activity leaching out into the supernatant at different time periods using the above technique. For the final application, 90 Y-labelled Biorex 70 microspheres were suspended in 2 ml PBS. To study the in vivo retention pattern of 90 Y-Biorex microspheres, the radioactive preparation was administered into the N1S1 tumour bearing rats by injection using 30G 1/2" needle as per previously reported protocol 27 . Prior to administration, the animals were fasted for six hours, and the procedure was performed under anaesthesia with a mixture of xylazine:ketamine (1:10). The 90 Y-labelled microspheres (50 μl) were slowly injected (20-25 sec) into the hepatic vessel via a 30G 1/2" needle. The site of injection was gently pressed with a gauze pad to stem any bleeding and then the incision was closed up with surgical suture. At the end of the procedure, the animals recovered from anaesthesia. Post recovery, food and water were provided ad libitum and they were kept under normal conditions till the time of sacrifice/ biodistribution and closely monitored during this period for any signs of disability or distress. At the end of the respective incubation periods, the animals were sacrificed by exposure to carbon dioxide saturated atmosphere. Blood was collected by cardiac puncture. The animals were then dissected and the relevant organs and tissues were excised for measurement of associated radioactivity to assess leaching of the radiolabelled preparation from the region of interest and its subsequent spread to non-specific regions.
Using 90 Y-labelled oxine in lipiodol, previously reported as a potential HCC therapy agent 24 .
Biological efficacy was assessed with a combination of biochemical and histological assays. For this, a separate set of tumour-bearing animals (4 animals per time-point, 3 × 10 6 cells per animal) administered with unlabelled "cold" preparation was used as a control for comparison. Serum was separated for relevant biochemical assays, including ALT and AST activity for liver function assessment, and alpha-foetoprotein (AFP) concentration as a marker of HCC. Liver tumour tissue samples were taken for histological analysis to assess biological efficacy of the therapeutic preparations by the following protocol: Samples of liver tissue were suspended in 10 per cent neutral buffered formalin for 24-48 h for preservation of the tissue structure. These were washed several times with water to remove all traces of formalin. Finally, these were suspended in 70 per cent ethanol solution for preservation and stored at 4°C, allowing adequate time for decay of 90 Y radioactivity (10 times half-life), before preparation of histological blocks and slides.
All quantitative results were reported as mean±SD, unless otherwise indicated. Applying Student's t-test, P values for the relevant biochemical parameters of the different treatment groups were calculated taking corresponding mean value of 4-week N1S1 tumour control as a hypothetical mean.
Results
The in-house electrochemical 90 Sr/ 90 Y generator was effective in providing ~3.7GBq of no-carrieradded (NCA) 90 Y per batch 23 , which could be separated in ≥90 per cent yield. The level of 90 Sr in the separated 90 Y was well within the permissible limits (<0.0005%), as estimated by extraction paper chromatography 23 .
Preparation of 90 Y-labelled Biorex 70 microspheres:
There was no variation in radiolabelling yield with reaction time. It was evident that the binding of 90 Y to the cationic Biorex 70 resin microspheres was extremely rapid; as early as 15 min, the labelling yield was ~95 per cent, which was retained up to 55 min. Stability in PBS was also excellent, with >95 per cent of the 90 Y-activity associated with the microspheres for as long as seven days post-preparation at 37°C (Fig. 1) .
In vivo distribution studies: Fig. 2a (Fig. 3) .
Biological efficacy studies:
To assess biological efficacy of the Values are mean ± SD (n=4) (Fig. 5a, b) . These levels were slightly increased over the values for N1S1 tumour controls (4 wk), referred above. Serum alphafoetoprotein levels show good correlation with tumour reduction (Fig. 5c ). In the case of animals administered with 90 Y-labelled Biorex 70 microspheres, the mean serum AFP level at seven days p.i. (19.49±3.72 mg/ ml), was significantly lower than for cold Biorex 70 microspheres (32.29±5.12 ng/ml, P<0.01) and less than half of the value for the N1S1 control animals at four weeks (51.44±11.97 ng/ml) corresponding with the reduced tumour size in those animals. 
Discussion
In this study, commercially Y-labelled oxine in lipiodol prepared using a previously reported protocol 24 . In a previously reported study 28 , Biorex 70 microspheres labelled with PET isotope yttrium-86 ( 86 Y) were tested for their in vivo stability in terms of pulmonary retention after tail vein catheterization; the results of imaging studies showed stable retention in the lung for up to 24 h post-administration. In the current study, Lu-labelled oxine in lipiodol 27 . It is proposed that 90 Y does not remain stably attached to oxine in vivo and leaches out as free 90 Y, which then accumulates in the bone. Yu et al 24 had studied in vivo distribution for only up to 48 h, and their observations were by way of Bremsstrahlung imaging using absence of 90 Y-activity in the lungs as an index of stable hepatic retention. This pharmacokinetic profile in our study suggests that 90 Y-labelled Biorex 70 microspheres would be safer in terms of nonspecific dose and therapeutically more effective due to significantly longer stable localization in the region of interest. The mean ratio of tumour to liver weight in the case of animals administered with 90 Y-labelled Biorex 70 microspheres was almost 50 per cent that of those treated with cold Biorex 70, indicating a significant gross impact of 90 Y radiation on the tumour lesion. The fall in serum AFP in these animals complemented the above observation. Although the AFP levels were still significantly above normal, perhaps on account of residual tumour tissue, this demonstrates that sustained presence of 90 Y activity from the microspheres gives a measurable therapeutic effect in the tested model for hepatocellular carcinoma.
In conclusion, the high 90 Y-labelling yield, high stability of labelled product, stable retention in the region of interest in the tested animal model, and demonstrable therapeutic effect as seen from measurement of relevant parameters in the period of study, indicate that Biorex 70 microspheres hold good potential to be taken up for further studies towards possible use in the clinic.
